Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Japan to Cut Drug Prices by 1.35% on Medical Cost Basis; No Special Rule for Adjustment Rate This Time
December 22, 2021
- AZ’s COVID-19 Drug to Be Reviewed with Priority if Filed in Japan: Senior Vice Minister
December 22, 2021
- Gist of FY2022 Drug Pricing Reform
December 22, 2021
- Look into Relationship Between COVID-19 Vaccination and Adverse Events: MHLW Panel
December 22, 2021
- Mochida’s Inhaled Treprostinil Gets Orphan Status
December 22, 2021
- Japan Expected to Cut Drug, Medical Device Prices by 160 Billion Yen on National Offers Basis
December 21, 2021
- MHLW Panel OKs “Specific-Use” Drug Designation for Dexmedetomidine
December 21, 2021
- Japan Likely to Expand PMP Coverage for Add’l Indications, Set 4-Year Grace Period for Spillover Exclusion: 2022 Reform
December 21, 2021
- Noxafil Contraindicated for Combined Use with Lonasen, Belsomra
December 20, 2021
- PM Kishida Vows to Move Up Booster, Offer COVID-19 Pill as Japan Girds for Omicron
December 20, 2021
- MSD’s Molnupiravir Up for PAFSC Review on Dec. 24
December 20, 2021
- Moderna COVID-19 Booster to Start from December 17
December 17, 2021
- Japan Approves Moderna Vaccine for COVID-19 Booster
December 16, 2021
- LDP Study Group Proposal Calls for 2%-Plus Adjustment Rate for 2022 Drug Price Revision
December 16, 2021
- Chuikyo Backs MHLW Proposal on Fertility Treatment Coverage
December 16, 2021
- Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
- Japan to Boost Pharma Startup Ecosystem via VC Certification Program, Allocates 50 Billion Yen in FY2021 Extra Budget
December 15, 2021
- Aducanumab Up for Japan Advisory Panel Review on December 22
December 15, 2021
- MHLW Calls for Lifting of Shipment Restrictions for 130 Generic API/Specifications after Survey Finds YOY Rise in Supplies
December 14, 2021
- Doctor, Pharmacist Reps Call for Expanding Fees for Biosimilars: Chuikyo
December 13, 2021
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…